ModifiedColorado Rocky Mountain Health PlansPolicy N/A
Xolair (omalizumab) Coverage and Prior Authorization
Customize your policy alerts
Sign up for all Colorado Rocky Mountain Health Plans policy alerts
Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This policy governs prior authorization and medical-necessity coverage for self-administered subcutaneous Xolair prefilled syringe and prefilled autoinjector formulations. It establishes initial authorization and reauthorization requirements for asthma and chronic urticaria and describes covered indications and limitations of use.
Policy Summary
PayerColorado Rocky Mountain Health Plans
PolicyXolair (omalizumab) Coverage and Prior Authorization
Policy CodePolicy N/A
Change TypeModified
Effective DateNov 1, 2026
Last ReviewApr 1, 2026
Next Review DateN/A
Key ActionDocument that Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
The policy requires that Xolair not be used with specified interleukin-4, interleukin-5, or TSLP therapies for the same indication.
Exdensur was added to the examples of anti-interleukin-5 inhibitors that must not be used in combination with Xolair.
The chronic urticaria prerequisite therapy criteria were updated.
4FDA-indicated conditions described
12 monthsInitial authorization duration
30–1300 IU/mL
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
Asthma IgE range
3Restricted combination therapy classes
>12 weeksNasal-polyp symptom duration
Epinephrine accessFood allergy requirement
Coverage Criteria
Asthma — Initial Authorization
Xolair is covered for moderate to severe persistent asthma when ALL applicable criteria in at least ONE pathway are met.
ONE of the following pathways
Established therapy pathway
Patient has been established on Xolair therapy for moderate to severe persistent asthma under an active medical benefit prior authorization.
Documentation of positive clinical response
Reduction in the frequency of exacerbations.
Decreased utilization of rescue medications.
Increase in percent predicted FEV1 from pretreatment baseline.
Reduction in severity or frequency of asthma-related symptoms, such as wheezing, shortness of breath, or coughing.
Xolair is being used in combination with an ICS-containing maintenance medication, such as Advair/AirDuo, Breo Ellipta, Symbicort, or Trelegy Ellipta.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or thymic stromal lymphopoietin (TSLP) inhibitor for the same indication.
New therapy pathway
Diagnosis of moderate to severe asthma.
Asthma is uncontrolled or inadequately controlled as demonstrated by at least ONE of the following
Poor symptom control, such as an Asthma Control Questionnaire (ACQ) score consistently greater than 1.5 or Asthma Control Test (ACT) score consistently less than 20.
Two or more bursts of systemic corticosteroids lasting at least 3 days each in the previous 12 months.
Asthma-related emergency treatment, including an emergency room visit, hospital admission, or unscheduled physician office visit for nebulizer or other urgent treatment.
Airflow limitation, such as post-bronchodilator FEV1 less than 80% predicted in the face of reduced FEV1/FVC below the lower limit of normal.
Asthma — Reauthorization
Xolair reauthorization requires ALL of the following criteria.
ALL of the following
Documentation of positive clinical response
Reduction in the frequency of exacerbations.
Decreased utilization of rescue medications.
Increase in percent predicted FEV1 from pretreatment baseline.
Reduction in severity or frequency of asthma-related symptoms, such as wheezing, shortness of breath, or coughing.
Xolair is being used in combination with an ICS-containing maintenance medication, such as Advair/AirDuo, Breo Ellipta, Symbicort, or Trelegy Ellipta.
Xolair is covered for chronic urticaria when ALL applicable criteria in at least ONE pathway are met.
ONE of the following pathways
Established therapy pathway
Patient has been established on Xolair therapy for chronic urticaria under an active medical benefit prior authorization.
Documentation of positive clinical response to Xolair therapy, such as reduction in exacerbations, itch severity, or hives.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
New therapy pathway
Diagnosis of chronic urticaria.
Chronic Urticaria — Initial Therapy Criteria
For the new-therapy pathway, ALL applicable criteria must be met.
ALL of the following
Diagnosis of chronic urticaria.
Patient remains symptomatic despite ONE of the following treatment histories
At least a 2-week trial of, or documented contraindication or intolerance to, two H1-antihistamines, such as Allegra, Benadryl, or Claritin.
At least a 2-week trial of updosing a second-generation H1-antihistamine up to 4-fold after being unresponsive to at least a 2-week trial of a standard-dose second-generation H1-antihistamine.
At least a 2-week trial of, or contraindication or intolerance to, BOTH of the following taken in combination
Chronic Urticaria — Reauthorization
Xolair reauthorization requires ALL of the following criteria.
ALL of the following
Documentation of positive clinical response to Xolair therapy, such as reduction in exacerbations, itch severity, or hives.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
Nasal Polyps — Initial Authorization
Xolair is covered for nasal polyps when ALL applicable criteria in at least ONE pathway are met.
ONE of the following pathways
Established therapy pathway
Patient has been established on Xolair therapy for nasal polyps under an active medical benefit prior authorization.
Documentation of positive clinical response to Xolair therapy.
Patient will continue Xolair as add-on maintenance therapy in combination with intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
Patient is not receiving Xolair in combination with an anti-interleukin 5 therapy, anti-interleukin 4 therapy, or TSLP inhibitor for the same indication.
Xolair reauthorization and maintenance therapy require ALL of the following criteria.
ALL of the following
Documentation of positive clinical response to Xolair therapy.
Patient will continue to receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
Patient is not receiving Xolair in combination with an anti-interleukin 5 therapy, anti-interleukin 4 therapy, or TSLP inhibitor for the same indication.
IgE-Mediated Food Allergy — Established Therapy
Xolair is covered for established IgE-mediated food allergy therapy when ALL criteria are met.
ALL of the following
Established therapy and response
Patient has been established on Xolair therapy for IgE-mediated food allergy under an active medical benefit prior authorization.
Documentation of positive clinical response to Xolair therapy, such as reduction in type I allergic reactions.
Xolair will be used in conjunction with food allergen avoidance.
Patient has access to epinephrine.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
IgE-Mediated Food Allergy — New Diagnosis
Xolair is covered for a new IgE-mediated food allergy diagnosis when ALL criteria are met.
ALL of the following
Diagnosis of IgE-mediated food allergy to one or more foods.
Patient is aged >= 1 year.
IgE-mediated food allergy to the specific food(s) is confirmed by BOTH of the following
History of type I allergic reactions, such as nausea, vomiting, cramping, diarrhea, flushing, pruritus, urticaria, swelling of the lips, face, or throat, wheezing, lightheadedness, or syncope.
One of the following confirmatory tests
Food-specific skin prick testing (SPT).
IgE-Mediated Food Allergy — Reauthorization
Xolair reauthorization requires ALL of the following criteria.
ALL of the following
Documentation of positive clinical response to Xolair therapy, such as reduction in type I allergic reactions.
Xolair will be used in conjunction with food allergen avoidance.
Patient has access to epinephrine.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
Prescriber is one of the following
Allergist.
Xolair is not indicated for acute bronchospasm or status asthmaticus; emergency treatment of allergic reactions, including anaphylaxis; or other forms of urticaria.
Xolair must not be used in combination with another biologic for treatment of the same indication, including anti-interleukin 4 therapy, anti-interleukin 5 therapy, or a thymic stromal lymphopoietin (TSLP) inhibitor.
For IgE-mediated food allergy, Xolair must not be used in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
Clinical Thresholds and Documentation Values
Baseline serum total IgE
Minimum serum total IgE≥ 30 IU/mL
Maximum serum total IgE≤ 1300 IU/mL
Required measurementBaseline pre-omalizumab serum total IgE
Asthma Control Questionnaire
Asthma Control Questionnaire thresholdConsistently greater than 1.5
Clinical useDefines poor symptom control
Assessment toolAsthma Control Questionnaire (ACQ)
Authorization, Documentation, and Denial Risks
Prior Authorization
Xolair Formulation and Administration Scope
Prior authorization applies to Xolair (omalizumab) prefilled syringe and prefilled autoinjector formulations used for self-administered subcutaneous therapy.
Covered formulation scope: prefilled syringe and prefilled autoinjector.
Route and use: self-administered subcutaneous injection.
Prior Authorization
Initial Asthma Authorization
For initial asthma authorization, submit documentation showing uncontrolled or inadequately controlled asthma despite intensive controller therapy, qualifying laboratory and allergy testing, and specialist prescribing.
Patient is at least 6 years old with moderate-to-severe persistent asthma.
Document poor symptom control, at least two systemic corticosteroid bursts of 3 or more days in the prior 12 months, asthma-related emergency treatment, qualifying airflow limitation, or current oral-corticosteroid dependence.
Use Xolair with a maximally dosed age-appropriate ICS/LABA combination plus one additional asthma controller medication.
Policy and Drug Background
Xolair (omalizumab) is an anti-IgE antibody. The policy describes coverage for moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria. Authorization criteria address clinical qualification, required concomitant therapy where applicable, documentation of response for continuation, and avoidance of specified concurrent biologic therapies.
Key Definitions
Uncontrolled or inadequately controlled asthma
Poor symptom controlAsthma Control Questionnaire score consistently greater than 1.5 or Asthma Control Test score consistently less than 20
Exacerbation historyTwo or more systemic corticosteroid bursts of at least 3 days each in the previous 12 months
Emergency treatmentAsthma-related emergency room visit, hospital admission, or unscheduled office visit for nebulizer or other urgent treatment
Airflow limitationFEV1 less than 80% predicted after appropriate bronchodilator withhold, with reduced FEV1/FVC below the lower limit of normal
Oral corticosteroid dependenceCurrent dependence on oral corticosteroids for asthma treatment
Chronic spontaneous urticaria
Initial Therapy Pathways
Asthma Initial Therapy
Asthma initial authorization requires one of two pathways.
Asthma initial therapy pathways
Established Xolair therapy
Positive clinical response: Reduction in exacerbations; decreased rescue-medication use; increased percent-predicted FEV1 from pretreatment baseline; or reduced severity or frequency of asthma-related symptoms.
New Xolair therapy
Uncontrolled or inadequately controlled asthma: Poor symptom control; at least two systemic corticosteroid bursts of at least 3 days each in the previous 12 months; asthma-related emergency treatment; airflow limitation; or current oral-corticosteroid dependence.
Reauthorization and Continuation
Asthma Reauthorization
Asthma reauthorization requires all of the following.
Asthma continuation: Positive clinical response to Xolair is documented; Xolair remains combined with an ICS-containing maintenance medication; and Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.Authorization duration: 12 months
Xolair Chronic Urticaria Continuation
Chronic urticaria continuation requires all of the following.
Chronic urticaria continuation: Positive clinical response to Xolair is documented, and Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.Authorization duration: 12 months
Required Prior Treatment
Step
Qualifying treatment history
Requirement
1
Trial of two H1-antihistamines
Persistent symptoms despite at least a 2-week trial of two H1-antihistamines; a documented contraindication or intolerance may substitute.
1
Updose a second-generation H1-antihistamine
Persistent symptoms despite at least a 2-week standard-dose trial followed by updosing up to 4-fold.
1
Combination antihistamine therapy
Persistent symptoms despite at least a 2-week trial of a second-generation H1-antihistamine combined with one additional therapy: a different second-generation H1-antihistamine, first-generation H1-antihistamine, H2-antihistamine, or leukotriene modifier; contraindication or intolerance may substitute.
Step
Qualifying treatment history
Requirement
1
Intranasal corticosteroid plus another nasal-polyp therapy
Unable to obtain symptom relief after intranasal corticosteroids plus nasal saline irrigation or an antileukotriene agent.
1
Systemic corticosteroid use
Required systemic corticosteroids for nasal polyps within the previous 2 years.
1
Prior sinus surgery
Required prior sinus surgery for nasal polyps.
Policy Summary
PayerColorado Rocky Mountain Health Plans
PolicyXolair (omalizumab) Coverage and Prior Authorization
Policy CodePolicy N/A
Change TypeModified
Effective DateNov 1, 2026
Last ReviewApr 1, 2026
Next Review DateN/A
Key ActionDocument that Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
Patient is currently dependent on oral corticosteroids for treatment of asthma.
Medical records document a baseline, pre-omalizumab serum total IgE level >= 30 IU/mL and <= 1300 IU/mL.
Positive skin test or in vitro reactivity to a perennial aeroallergen.
Xolair is used in combination with ONE of the following controller regimens
One maximally dosed, appropriately age-adjusted combination ICS/long-acting beta2 agonist (LABA), such as Advair/AirDuo Respiclick, Symbicort, or Breo Ellipta.
Combination therapy including both of the following
One maximally dosed, appropriately age-adjusted ICS product, such as Alvesco, Asmanex, or QVAR.
One additional asthma controller medication, such as a LABA, leukotriene receptor antagonist, or theophylline.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
Prescriber is one of the following
Allergist.
Immunologist.
Pulmonologist.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
Authorization will be issued for 12 months.
Reauthorization period.
A second-generation H1-antihistamine, such as Allegra, Claritin, or Zyrtec.
One additional therapy
A different second-generation H1-antihistamine.
A first-generation H1-antihistamine, such as Benadryl, Chlor-Trimeton, or Vistaril.
An H2-antihistamine, such as Pepcid, Tagamet HB, or Zantac.
A leukotriene modifier, such as Singulair.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
Prescriber is one of the following
Allergist.
Dermatologist.
Immunologist.
Diagnosis of nasal polyps.
At least TWO of the following symptoms for longer than 12 weeks
Nasal mucopurulent discharge.
Nasal obstruction, blockage, or congestion.
Facial pain, pressure, and/or fullness.
Reduction or loss of sense of smell.
At least ONE objective finding on nasal endoscopy and/or sinus CT
Purulent mucus or edema in the middle meatus or ethmoid regions.
Polyps in the nasal cavity or middle meatus.
Radiographic imaging demonstrating mucosal thickening or partial or complete opacification of the paranasal sinuses.
At least ONE of the following treatment histories
ALL of the following
Patient has been unable to obtain symptom relief after a trial of intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
AND one other therapy used in management of nasal polyps
Nasal saline irrigations.
Antileukotriene agent, such as montelukast, zafirlukast, or zileuton.
Patient has required systemic corticosteroids, such as prednisone or methylprednisolone, for nasal polyps in the previous 2 years.
Patient has required prior sinus surgery.
Patient will receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
Patient is not receiving Xolair in combination with an anti-interleukin 5 therapy, anti-interleukin 4 therapy, or TSLP inhibitor for the same indication.
Prescriber is one of the following
Allergist.
Immunologist.
Otolaryngologist.
Pulmonologist.
Prescriber is one of the following
Allergist.
Immunologist.
IgE antibody in vitro testing.
Oral food challenge (OFC).
Xolair will be used in conjunction with food allergen avoidance.
Patient has access to epinephrine.
Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
Prescriber is one of the following
Allergist.
Immunologist.
Immunologist.
Authorization will be issued for 12 months.
Reauthorization period.
Asthma Control Test
Asthma Control Test thresholdConsistently less than 20
Clinical useDefines poor symptom control
Assessment toolAsthma Control Test (ACT)
Airflow limitation thresholds
FEV1 thresholdLess than 80% predicted
Bronchodilator conditionMeasured after appropriate bronchodilator withhold
FEV1/FVC requirementReduced FEV1/FVC below the lower limit of normal
Systemic corticosteroid bursts
Number of burstsAt least 2 systemic corticosteroid bursts
Duration of each burstAt least 3 days each
Look-back periodPrevious 12 months
Second-generation H1-antihistamine updosing
Maximum updosingUp to 4-fold
Standard-dose trial before updosingAt least 2 weeks
Updosed-treatment trialAt least 2 weeks
Nasal-polyp symptom duration
Minimum symptom durationLonger than 12 weeks
Number of qualifying symptomsTwo or more
Examples of qualifying symptomsNasal mucopurulent discharge; nasal obstruction, blockage, or congestion; facial pain, pressure, or fullness; or reduced or lost sense of smell
Prior systemic corticosteroid use
Look-back periodPrevious 2 years
TreatmentSystemic corticosteroids, such as prednisone or methylprednisolone
Qualifying conditionRequired for nasal polyps when this treatment-history alternative is used
Prescriber must be an allergist, immunologist, or pulmonologist.
Prior Authorization
Asthma Reauthorization
Asthma reauthorization requires evidence that Xolair is working and that maintenance controller therapy continues. The patient must not receive another biologic for the same indication.
Document at least one response: fewer exacerbations, less rescue-medication use, increased percent-predicted FEV1, or reduced severity/frequency of wheezing, shortness of breath, coughing, or other asthma symptoms.
Continue an ICS-containing maintenance medication.
Do not combine with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
Prior Authorization
Initial Chronic Urticaria Authorization: Established Therapy
For initial chronic spontaneous urticaria authorization through the established-therapy pathway, document active prior authorization history, clinical response, and the required prescribing and combination-therapy safeguards.
Patient must already be established on Xolair for chronic urticaria under an active medical-benefit prior authorization.
Document positive clinical response, such as reduced exacerbations, itch severity, or hives.
Prescriber must be an allergist, dermatologist, or immunologist.
Do not combine with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
Documentation Required
Initial Chronic Urticaria Authorization: New Therapy
For a new chronic urticaria authorization, document the diagnosis and a qualifying history of persistent symptoms despite appropriate H1-antihistamine therapy or documented contraindication/intolerance.
Patient must have a diagnosis of chronic urticaria.
Submit the applicable antihistamine trial, updosing, combination-therapy, contraindication, or intolerance history.
Prescriber must be an allergist, dermatologist, or immunologist.
Do not combine with another prohibited biologic for the same indication.
Prior Authorization
Initial Nasal-Polyp Authorization
For initial nasal-polyp authorization, use either the established-therapy pathway or the new-therapy clinical qualification pathway. Both pathways require add-on intranasal corticosteroid therapy and appropriate specialist oversight.
Established therapy: document active prior authorization history, positive response, continued intranasal corticosteroid use, and specialist prescribing.
New therapy: document nasal-polyps diagnosis, qualifying symptoms lasting more than 12 weeks, objective endoscopy or CT findings, and required prior treatment history.
Prescriber must be an allergist, immunologist, otolaryngologist, or pulmonologist.
Do not combine with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
Prior Authorization
Initial Authorization Term
Initial authorization for Xolair is issued for 12 months when the applicable indication-specific criteria are met.
Authorization term: 12 months.
Prior Authorization
Established Food Allergy Therapy
For patients already receiving Xolair for IgE-mediated food allergy, document the existing authorization, positive response, safety measures, avoidance plan, and specialist prescriber.
Document established Xolair therapy under an active prior authorization and positive response, such as reduced type I allergic reactions.
Xolair must be used with food-allergen avoidance.
Patient must have access to epinephrine.
Prescriber must be an allergist or immunologist.
Do not combine with another prohibited biologic for the same indication.
Prior Authorization
Initial Food Allergy Authorization
For a new food-allergy authorization, submit documentation confirming IgE-mediated allergy and the patient's age, safety plan, avoidance plan, and specialist prescriber.
Patient must be at least 1 year old and have IgE-mediated food allergy to one or more foods.
Confirm the specific food allergy with both a history of type I allergic reactions and food-specific skin-prick testing, in-vitro IgE testing, or an oral food challenge.
Xolair must be used with food-allergen avoidance, and the patient must have access to epinephrine.
Prescriber must be an allergist or immunologist.
Step Therapy
Chronic Urticaria Antihistamine Step Therapy
For chronic urticaria, document that symptoms persist despite an adequate H1-antihistamine step-therapy trial or that the required therapies are contraindicated or not tolerated.
At least 2 weeks of two H1-antihistamines; or
At least 2 weeks of up-dosing a second-generation H1-antihistamine up to fourfold after failure of at least 2 weeks at standard dose; or
At least 2 weeks of a second-generation H1-antihistamine combined with a different second-generation H1-antihistamine, first-generation H1-antihistamine, H2-antihistamine, or leukotriene modifier.
Document contraindication or intolerance when used instead of a trial.
Step Therapy
Nasal-Polyp Treatment History
For nasal polyps, document prior treatment with intranasal corticosteroids and another accepted management therapy, or qualifying systemic corticosteroid or surgical history.
Document inability to obtain symptom relief after intranasal corticosteroids plus nasal saline irrigation or an antileukotriene agent.
Alternatively, document systemic corticosteroid use for nasal polyps within the prior 2 years or prior sinus surgery.
Continue intranasal corticosteroid therapy as add-on maintenance treatment.
Unsupported block type: documentation under physician?
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: denial_risk
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: denial_risk
Denial Risk
Concurrent Biologic Therapy
Do not submit Xolair concurrently with another biologic for treatment of the same indication.
Prohibited combinations include anti-interleukin-4 therapy, such as Dupixent (dupilumab).
Prohibited combinations include anti-interleukin-5 therapy, such as Cinqair, Exdensur, Fasenra, or Nucala.
Prohibited combinations include the TSLP inhibitor Tezspire (tezepelumab).
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: documentation
Unsupported block type: prior_auth
PopulationAdults and adolescents 12 years of age and older
Controller therapy: One maximally dosed, age-appropriate ICS/LABA combination, or a maximally dosed, age-appropriate ICS plus one additional asthma controller medication.
Chronic Urticaria Initial Therapy
Chronic urticaria initial therapy requires one of two pathways.
Chronic urticaria initial therapy pathways
Established Xolair therapy
Positive clinical response: Reduction in exacerbations, itch severity, or hives.
New chronic urticaria therapy
Qualifying antihistamine treatment: At least a 2-week trial of two H1-antihistamines; or up to four-fold updosing of a second-generation H1-antihistamine after nonresponse to at least a 2-week standard-dose trial; or at least a 2-week trial of specified combination antihistamine therapy.
Xolair for Chronic Urticaria
Xolair initial therapy for chronic urticaria requires all of the following.
Chronic urticaria qualification
Qualifying antihistamine treatment
Persistent symptoms despite at least a 2-week trial of, or contraindication or intolerance to, two H1-antihistamines.
Persistent symptoms despite at least a 2-week trial of a second-generation H1-antihistamine updosed up to four-fold after nonresponse to at least a 2-week standard-dose trial.Up to 4-fold
Persistent symptoms despite at least a 2-week trial of, or contraindication or intolerance to, a second-generation H1-antihistamine combined with a different second-generation H1-antihistamine, first-generation H1-antihistamine, H2-antihistamine, or leukotriene modifier.
Established Therapy
The established food allergy therapy pathway requires all of the following.
Established IgE-mediated food allergy therapy: Established Xolair therapy for IgE-mediated food allergy under an active UnitedHealthcare medical benefit prior authorization; documented positive clinical response; use with food allergen avoidance; access to epinephrine; no prohibited same-indication biologic combination; and prescribing by an allergist or immunologist.Authorization duration: 12 months
New IgE-Mediated Food Allergy
The newly evaluated patient pathway requires all of the following.
New IgE-mediated food allergy: Diagnosis of IgE-mediated food allergy to one or more foods; age at least 1 year; history of type I allergic reactions; confirmation by food-specific skin-prick testing, IgE antibody in-vitro testing, or oral food challenge; food allergen avoidance; epinephrine access; no prohibited same-indication biologic combination; and prescribing by an allergist or immunologist.Age ≥1 year
Authorization duration: 12 months
Xolair Nasal-Polyp Continuation
Nasal-polyp continuation requires all of the following.
Nasal-polyp continuation: Positive clinical response to Xolair is documented; Xolair continues as add-on maintenance therapy with intranasal corticosteroids; and Xolair is not used with an anti-interleukin-5 therapy, anti-interleukin-4 therapy, or TSLP inhibitor for the same indication.
Continuation—Maintenance Therapy
Continuation requires all of the following.
Continued maintenance therapy: Positive clinical response to Xolair is documented; Xolair continues as add-on maintenance therapy with intranasal corticosteroids; and Xolair is not used with an anti-interleukin-5 therapy, anti-interleukin-4 therapy, or TSLP inhibitor for the same indication.Authorization duration: 12 months
Continuation—IgE-Mediated Food Allergy
Food allergy continuation requires all of the following.
Continued IgE-mediated food allergy therapy: Positive clinical response to Xolair is documented; Xolair is used with food allergen avoidance; the patient has access to epinephrine; Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication; and the prescriber is an allergist or immunologist.Authorization duration: 12 months